Searched for
GLOBAL PHARMACEUTICAL MARKET
SCHOTT Pharma India marks a new chapter, building on its strong national presence and global capabilitiesNew identity reinforces the company’s focus on innovation, customer partnerships and pharmaceutical drug containment and delivery solutions- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhen a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling u...
- India, Mexico begin talks for trade pact; aim to boost commerce, investmentsIndia and Mexico have initiated negotiations for a preferential trade agreement to enhance bilateral trade and investment. The agreement ai...
- India, Mexico sign terms of reference to kickstart trade pact negotiationsIndia and Mexico have signed the Terms of Reference to initiate negotiations on a Preferential Trade Agreement. This agreement aims to enha...
- Cipla sets sights on first-wave gains from rollout of Keytruda BiosimilarCipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...
- Anthropic IPO: Here are some of the key people of Indian origin behind the AI giantAs the artificial intelligence company prepares for the next phase in its journey, let’s take a look at several top people in the organisat...
- Market wrap: Bharti Airtel, Tata Consumer, Asian Paints, Coal India top gainers and losers on Nifty and Sensex on TuesdayIndian equity benchmarks ended nearly flat on Tuesday, with the Nifty 50 slipping 0.02% and the Sensex falling 8 points amid elevated crude...
- Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- AI halves drug discovery times, but =trial bottleneck remains a costly realityNovo Nordisk, Sanofi and Dr Reddy’s Laboratories are among the companies exploring applications ranging from drug discovery to laboratory a...
- Indian markets rebound, but rising oil prices keep investors cautiousOn Monday, Indian equity markets staged a comeback following four days of losses, with both the BSE Sensex and NSE Nifty seeing notable gai...
- DRL says cap on trade margins a positive, posts 36% dip in Q2 PATIn the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...
- Commerce minister Piyush Goyal discusses investment avenues with German companiesPiyush Goyal engaged with major German firms like Siemens Healthineers, Bayer, and Fresenius to discuss investments. He highlighted Bayer's...
- Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginallyDr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America ...
- GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
- Piyush Goyal discusses investment opportunities with Bayer, FreseniusPiyush Goyal held meetings with Bayer and Fresenius executives to discuss investment opportunities in India's healthcare sector. During the...
- ETMarkets Smart Talk: Smallcap investors should consider a five-year SIP horizon amid volatility: Sorbh GuptaIn an interview with Kshitij Anand of ETMarkets, Sorbh Gupta, Head of Equity at Bajaj Asset Management Limited, says investors considering ...
- Himadri Speciality Chemicals plans Rs 1,613-cr capacity expansion across key businessesHimadri Speciality Chemicals Ltd is implementing a growth strategy focused on capacity expansion and investment. The company plans to inves...
- Europe’s last penicillin plant faces a bitter fight against China’s cheaper drugsThe Sandoz penicillin plant in Kundl, Austria, is under threat from cheaper Chinese antibiotic production. European healthcare programs ben...
- Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select playersIndia's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...
Load More
